Mayo Clinic researchers found a drug developed in the 1940s [3] activates a previously unknown kidney water-balance pathway.

This discovery provides a potential new therapeutic avenue for treating chronic kidney disease and polycystic kidney disease by targeting a novel mechanism of water regulation. Such a breakthrough could lead to treatments that slow or even reverse the progression of these debilitating conditions.

Dr. Fouad Chebib and his team at the Mayo Clinic in Rochester, Minnesota, identified the pathway through their research. The drug, which dates back to the 1940s [3], reveals how the kidneys regulate water balance in a way that was previously unrecognized by science. By exploiting this specific target, researchers believe they can develop new interventions for kidney failure.

The scale of the need for such treatments is significant. Approximately 800 million [2] people worldwide live with chronic kidney disease. Current medical approaches often focus on managing symptoms or slowing decline, but the identification of this specific pathway offers a more precise biological target for drug development.

While this research focuses on the 1940s-era medication, other studies have explored different pharmacological paths. For example, separate research into a constipation drug involved a clinical trial of 150 patients [1]. However, the Mayo Clinic findings specifically highlight the ability of the older drug to uncover this specific water-balance mechanism.

The research suggests that the kidney's ability to maintain fluid homeostasis is more complex than previously understood. By activating this pathway, the medication may protect kidney function or mitigate the damage caused by genetic or chronic conditions. The team is now looking toward how this mechanism can be translated into clinical applications for the millions of patients affected by renal failure.

“A drug first developed in the 1940s has been shown to activate a previously unknown kidney water‑balance pathway.”

The identification of a new biological pathway using an existing drug significantly reduces the early-stage discovery risk for new treatments. By repurposing the knowledge of a 1940s-era compound, researchers have found a 'key' to a 'lock' in kidney function that was previously hidden, potentially shifting the treatment paradigm from general symptom management to targeted pathway modulation for chronic kidney disease.